I know it's an old thread, but if I may ask: Why is it important how potent the MAB is, given that Rituximab at doses used in the Norwegian trials usually destroys all B cells and they are 0 in the blood after just a few days?
Couldn't a more potent antibody just destroy them a few days faster? Given the timeframe for response to treatment (2-6 months minimum), this shouldn't matter much, right?